MIT PROCESSING , Made in Taiwan
- 店家商品
- 微生物專用設備 細胞專用設備 基礎理化設備 溶液處理移液設備 蛋白質專用設備 Cellpro 試劑類 培養基類 實驗室耗材類 儀器維修&校正服務 防疫專區 infitek系列 pakgent系列 塑膠耗材類別 冷藏冰箱
0972064
喬智生技-實驗室規劃,實驗室耗材批發,台中實驗室規劃,台中實驗室耗材批發
店家商品
Description
POCT Fully Quantitative Immunofluorescence Analyzer
Most Stable Rare Earth Material Time-Resolved
Immunofluorescence Methodology
Top Quality POCT Immunofluorescence Platform
Platform Features
Sample Types: Serum, Whole Blood, Plasma, Fingertip Blood, Urine…
Parameters:Diabetes,Kidney Function,Infection,Cardiac Function,Gastric Function…
Comprehensive
Various assays
Comprehensive sample types
Simple and Convenient
Small size, space -saved, stacked incubators
Convenient operation, no requirement for professional skills
Accuracy
Constant incubation, corruption prevention,
low coefficient variance Precise quality control, accurate results
Rapidity
Point of care testing
Instant results analysis in 10 seconds
Specifications
| Subject | Performance parameter |
| Detection speed | 10 sec/test |
| Time of first result | 5-15min |
| Sample position | 8 channel (stackable) |
| LIS system | Support ASTM and HL7 |
| Size(mm) | 500x400x400mm |
| Net/Gross Weight | 8.5/9kg |
| Control | Embedded integrated machine |
| Interface | Graphical operation interface |
| Status monitor | Real-time intelligent monitoring |
| Repeatability | CV≤15% |
|
Fluorescence
Rare Earth Fluorescence life-span is longer than Quantum |
|
| Fluorescent materials | Life-span |
| Fluorescent rare earth | 714000 ns |
| Quantum | 20-50 ns |
| Nonspecific fluorescent particle | 1-10 ns |
Rare earth fluorescence has larger stokes shift, higher signal-to noise ratio (SNR) and higher sensitivity compared to other markers
Rare earth fluorescence has high quantum yield, high fluorescent efficiency, and wide linear range
Menu of assays
| Biomarkers | Abbr. | Specimen | Instruction for Use | Expected values | Measuring range | |
| Inflammation |
Procalcitonin
|
PCT | Serum/Whole Blood | lndicate sepsis and bacterial infection | <0.05 ng/mL | 0.05-100 ng/mL |
|
Full Range C-reactive Protein |
CRP | Plasma/Whole Blood | Low risk of cardiovascular disease Medium risk of cardiovascular disease ·High risk of cardiovascular disease Detecting conventional inflammation | hs-CRP:<1.0mg/L hs-CRP:1.0-3.0mg/L hs-CRP:>3.0mg/L CRP:≤10 mg/L | 0.5-200 mg/L | |
| C-reactive Protein/Amyloid proteinase A 2-in-1 | CRP/SAA | Plasma/Whole Blood |
·Low risk of cardiovascular disease ·Medium risk of cardiovascular disease ·High risk of cardiovascular disease Detecting conventional inflammation |
hs-CRP: <10mg/L hs-CRP:1.0-3.0mg/L hs-CRP: >3.0mg/L CRP:≤10 mg/L |
0.5-200 mg/L | |
| Immune | Rheumatism 3-in-1 | ASO/RF/CRP |
Serum/Plasma/ Whole Blood |
lndicators of systemic inflammation ·To assist in the diagnosis,classification and prognosis of rheumatoid arthritis |
ASO:≤200 IU/mL RF:≤20IU/mL CRP:≤10 mg/L |
ASO:50-500 IU/mL RF:10-200 IU/mL CRP:0.5-200 mg/L |
| *Anti cyclic citrullinated peptide antibody | Anti-CCP | Serum/Plasma/Whole Blood | ·Assistant diagnostic indexe of rheumatoid arthritis | s25 U/mL | 25-1000 U/mL | |
| Cardiovascular | Cardiac Troponin I | cTnl | Serum/Plasma/Whole Blood | ·Diagnose AMI,risk stratification and evaluate prognosis Value markers of non ST segment elevation MI | ≤0.3 ng/mL | 0.1-50 ng/mL |
| Creatine Kinase-MB | CK-MB | Serum/Plasma/Whole Blood | ·Negative exclusion of early AMI; Detection of recurrence and thrombolytic therapy | ≤5 ng/mL | 1-100 ng/mL | |
| Myoglobin | MYO | Serum/Plasma/Whole Blood | Early diagnosis of AMI | s70 ng/mL | 5-500 ng/mL | |
| Myocardial Infarction(MI) 3-in-1 |
cTnl/MYO/ CK-MB |
Serum/Plasma/Whole Blood | Same as above 3 markers | cTnl:≤03ng/mL MYO=70 ng/mL CK-MB:≤5ng/mL | cTnl:01-50 ng/mL MYO:5-500 ng/mL CK-MB:1-100 ng/mL | |
| D-Dimer(D-Dimer) | D-Dimer | Plasma/Whole Blood | Exclusion and diagnosis of venous thromboembolism | ≤0.5 mg/L | 0.1-10 mg/L | |
| N-terminal B-type natriuretic peptide | NT-proBNP | Serum/Plasma/Whole Blood | Diagnosis heart failure,risk stratification and prognostic evaluation | ≤300 pg/mL | 50-35000 pg/mL | |
| *Lipoprotein-Associated Phospholipase A2 | Lp-PLA2 | Serum/Plasma/Whole Blood | lndicating the stability of atherosclerotic plaque ·Predicting the risk of coronary heart disease and stroke | s200ng/mL | 20-1000 ng/mL | |
| *cTnl/NT-proBNP/D-Dimer 3-in-1 |
cTnl/ NT-proBNP/ D-Dimer |
Plasma/Whole Blood | Same as above 3 markers | ctnl:s03ng/mL NT-proBNP:≤300 pg/mL D-Dimer:≤0.5 mg/L | cTnl:01-50 ng/mL NT-proBNP:100-20000 pg/mL D-Dimer:0.1-10 mg/L | |
其它相關店家資訊
免責聲明本網站僅提供製造業公司資訊參考平台， 並不涉入其中任何諮詢、交易。本網站對各該製造業公司相關資訊亦不作任何實質或形式上之審查。就本網站中所載一切製造業公司的資訊、文字、照片、圖形 、產權、廣告內容、或其他資料（以下簡稱『內容』），無論其為公開張貼或私下傳送，若有不實或違法情事，均為『內容』提供者之責任，本站概不負責也不承擔任何法律責任